Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia
Open Access
- 22 May 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7, 254
Abstract
Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 PneumoniaKeywords
This publication has 21 references indexed in Scilit:
- The novel surfactant protein SP-H enhances the phagocytosis efficiency of macrophage-like cell lines U937 and MH-SBMC Research Notes, 2014
- SFTA2—A Novel Secretory Peptide Highly Expressed in the Lung—Is Modulated by Lipopolysaccharide but Not HyperoxiaPLOS ONE, 2012
- What’s new in surfactant?European Journal of Pediatrics, 2007
- The “wisdom” of lung surfactant: balancing host defense and surface tension-reducing functionsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDSJournal of Perinatology, 2006
- Biology of alveolar type II cellsRespirology, 2006
- Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2004
- Pulmonary Surfactant: The Key to the Evolution of Air BreathingPhysiology, 2003
- Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trialThe Lancet, 2000
- Surfactant Replacement Therapy for Meconium Aspiration SyndromePediatrics, 1996